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Abstract: Cancer patients frequently suffer from fatigue, a complex
syndrome associated with tiredness and depressed mood. Cancer-related
fatigue (CRF) can be present at the time of diagnosis, escalates during
treatment, and can persist for years after treatment. CRF negatively
influences quality of life, limits functional independence, and is associated
with decreased survival in patients with incurable disease. We have previously
shown that increased pro-inflammatory cytokine expression in the brain
contributes to depressive- and fatigue- like behaviors in a mouse model of
CRF. Inflammatory cytokines increase activity of indoleamine 2,3-dioxygenase
(IDO) and kynurenine 3-monooxygenase (KMO), which competitively reduce
serotonin synthesis. Reduced serotonin availability in the brain and increased
production of alternative neuroactive metabolites of tryptophan are thought to
contribute to the development of depression and fatigue. The purpose of this
study was to determine the effects of fluoxetine, a selective serotonin
reuptake inhibitor (SSRI), on brain cytokines and behavioral measures of
fatigue and depression in tumor-bearing mice. Here we show that tumor
growth increased brain expression of pro-inflammatory cytokines and KMO.
Treatment with fluoxetine had no effect on tumor growth, muscle wasting,
fatigue behavior, or cytokine expression in the brain. Fluoxetine, however,
reduced depressive-like behaviors in tumor bearing mice. In conclusion, our
data confirm that increased brain expression of pro-inflammatory cytokines is
associated with tumor-induced fatigue and depressive-like behavior. However,
it is possible to separate the effects of tumor growth on mood and fatigue-like
behaviors using SSRI’s such as fluoxetine.
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1. Introduction
Cancer related fatigue (CRF) is the most common and most
distressing symptom reported by cancer patients. CRF is characterized
by overwhelming tiredness and lack of energy which significantly
reduce quality of life.1 Importantly, fatigue is reported by cancer
patients before and during treatment, and can continue for years after
completion of treatment.2–4 In addition, CRF is frequently associated
with depressed mood,5–7 although the mechanism for this association
is unclear. A recent report8 suggests that pre-existing psychological
conditions, such as depressed mood, increase the risk of persistent
fatigue after completion of treatment. Others reported that treatment
of cancer patients with antidepressant medications, such as selective
serotonin reuptake inhibitors (SSRI), during chemotherapy improved
mood but did not affect patient reports of fatigue.9, 10 Others found
that treatment with modafinil improved fatigue, but not depression, in
cancer patients during chemotherapy.11
The association between symptoms of depression and fatigue in
cancer patients suggests a common pathological pathway. Mounting
evidence from both clinical and preclinical studies indicates that
elevations in pro-inflammatory cytokines may function as a common
mechanism for the frequent association of fatigue and depression in
patients with CRF. For instance, elevated serum levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNFα),
interleukin (IL)-1β and IL-6, are associated with fatigue in cancer
patients.12, 13 Increases in systemic inflammation are relayed to the
brain where inflammation is propagated by innate immune cells.14
Increased neuroinflammation, for example increased brain IL-1β
expression, has been linked to both depressed mood15 and fatigue.16
Using a mouse model of CRF, we have previously shown that increased
expression of pro-inflammatory cytokines within the CNS is associated
with behavioral measures of fatigue, such as decreased voluntary
wheel running (VWRA) activity, measures of weakness, such as
reduced grip strength, and depressed mood, such as immobility during
the forced swim test (FST) and anhedonia.17 Treatment with
minocycline, a drug that reduces brain synthesis of inflammatory
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cytokines, reduced depressive-like behaviors and improved grip
strength in tumor-bearing mice.17
There are several proposed mechanisms by which increased
neuroinflammation can lead to altered mood. Inflammatory cytokines
increase expression and activity of the tryptophan degrading enzymes
indoleamine 2,3-dioxygenase (IDO) and kynurenine 3-monooxygenase
(KMO), which competitively inhibits activity of tryptophan hydroxylase
(TPH) for metabolism of tryptophan to serotonin. Increased tryptophan
metabolism by IDO into neuroactive metabolites leads to an imbalance
in serotonin neurotransmission and subsequent development of
depression.18, 19 Inflammatory cytokines also increase expression and
activity of the serotonin transporter.20 A recent study showed that
peripheral tumors altered serotonin signaling pathways and decreased
overall serotonin levels in the hypothalamus of tumor bearing mice.21
The purpose of the present study was to examine the effect of
fluoxetine, a selective serotonin reuptake inhibitor (SSRI), on brain
expression of pro-inflammatory cytokines and behaviors of fatigue and
depressed mood in tumor bearing mice.

2. Materials and methods
2.1 Mice
Adult (10 weeks) female BALB/c×DBA/2 F1 (CD2F1) mice
weighing 20–22 g were obtained from Charles River Laboratories.
Female mice were used because we and others have shown that
tumor-bearing females maintain their food intake longer and lose a
smaller percent of body mass than male mice22 and male mice tend to
gnaw and bite at the tumor site more than females, causing local
inflammation.23 Mice were singly housed and maintained at 25°C
under a 12 h light cycle with ad libitum access to water and rodent
chow. All procedures were performed in accordance with the National
Institute of Health Guidelines for the Care and Use of Laboratory
Animals and were approved by The Ohio State University Institutional
Animal Care and Use Committee.
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2.2 Mouse model of tumor-growth
The colon26 adenocarcinoma (colon26) cell line was maintained
in culture and prepared for injection as previously described.24 Mice
were injected subcutaneously between the scapulae with 5×105 cells in
0.2 ml of PBS or PBS alone. This tumor cell line is syngeneic for CD2F1
mice and secretes IL-6 and TNF-α25 and does not metastasize when
injected subcutaneously.26 Tumor growth is usually palpable by day 7;
weight loss, splenomegaly, and muscle wasting are evident after day
14, and mice become moribund by day 24 of tumor-growth. In the
present study, all data collection was completed by day 21 of tumor
growth. Body weight was monitored three times a week for the first
two weeks, and daily during the third week. Mice were euthanized by
inhalation of CO2 gas on day 21 of tumor growth. Gastrocnemius
muscles, spleen, and tumor were dissected and weighed; the brain
was quickly dissected and hippocampus brain tissue was snap frozen in
liquid nitrogen. Carcass weight was determined by subtracting tumor
weight from body weight at the time of sacrifice.

2.3 Oral Fluoxetine administration
Fluoxetine (Sigma, St. Louis) was administered in the drinking
water at a dose of 3 mg/kg/day (Sigma, St. Louis) starting one day
after injection of PBS or tumor cells. This dose of fluoxetine has
previously been shown to block depressive-like behavior in mice
without affecting locomotor activity of healthy mice.27 Water intake
was monitored every other day. There was no difference between fluid
intakes during the first two weeks of tumor growth. During week
three, both tumor groups had increased water intake, but there was
no difference between water and fluoxetine intake in the tumor
animals. Water bottles were changed weekly throughout the study.
Fluoxetine diluted in water has previously been shown to be stable for
8 weeks at room temperature.28

2.4 Voluntary wheel running activity
Fatigue-like behavior was determined using voluntary wheel
running activity (VWRA).29 Mice were singly housed and acclimated to
a four inch diameter running wheel in the cage for one week, and
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baseline measures (week 0) of VWRA were recorded overnight prior to
injection with tumor cells or PBS. Wheels were again placed in the
home cages of all mice overnight (6 p.m. to 8 a.m.) on days 8 (week
1), 14 (week 2) and 19 (week 3) of tumor growth and the total
number of turns each night was digitally recorded (Columbus
Instruments, model 0297-004M).

2.5 Home cage locomotor activity
Home cage locomotor activity test was performed between
4:30–6pm, before the beginning of the dark cycle when mice become
more active and there is minimal disturbance in the vivarium. Mice
were maintained in their home cage with a floor area of 26×20 cm,
and activity was video recorded for 3 minutes. On the video records,
cages were divided into 6 identical virtual rectangles and the number
of line crossings was determined.

2.6 Depressive-like behavior
Depressive-like behavior was determined on day 13 using the
forced swim test (FST) as described previously.30 The FST was
performed following the home cage locomotor test between 4:30–
6pm. Mice were placed in an inescapable cylinder (diameter 16 cm,
height 30 cm) containing 15 cm of water and behavior was recorded
for five min. The latency to become immobile and the duration of
immobility were determined.

2.7 RNA isolation and RT-PCR analysis
RNA was isolated from hippocampus brain sections using the
Tri-Reagent protocol (Sigma) and reverse transcribed to cDNA using
the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Quantitative PCR was performed using the Applied
Biosystems Assay-on-Demand Gene Expression protocol. In brief,
experimental cDNA was amplified with an ABI PRISM 7300-sequence
detection system (Applied Biosystems) by real-time PCR and
normalized based on reference cDNA (GAPDH). Data were analyzed
with the comparative threshold cycle method. Data is expressed as
fold change from control-vehicle.
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2.8 Statistical Analysis
Data were subjected to a Shapiro-Wilk test using Statistical
Analysis Systems (SAS) software (Cary, NC). Observations greater
than three interquartile ranges from the first and third quartile were
considered outliers and were excluded in the subsequent analyses. To
determine significant main effects and interactions between main
factors, data were analyzed using one- or two- way ANOVA using the
General Linear Model procedures of SAS. Differences between group
means were evaluated with the t-test using the Least-Significant
Difference procedure of SAS. All data are expressed as treatment
means ± standard error of the mean (SEM).

3. Results
3.1 Effects of fluoxetine on tumor growth
Mice were treated with water (vehicle) or fluoxetine at
3mg/kg/day starting at one day after tumor cell inoculation to the
completion of the study. In this model, tumor bearing mice lose
significant muscle mass with the progression of tumor growth. Fig. 1A
shows total body weight throughout the study. At the completion of
the study (Day 21) tumor bearing mice had significantly decreased
carcass weight compared to healthy control mice (Fig.1B)
(F1,52=31.70, p<0.0001). There was no effect of fluoxetine on carcass
weight. Associated with decreased carcass weight, gastrocnemius
muscle mass was decreased in tumor-bearing mice compared to
healthy controls (F1,52=147.86, p<0.0001) and was not altered by
fluoxetine treatment (Fig.1C). Fluoxetine treatment had no effect on
tumor mass (Fig.1D) or spleen weight, a nonspecific measure of
systemic inflammation (Fig.1E). These data confirm that fluoxetine had
no effects on tumor growth, weight loss, or loss of muscle mass in the
tumor-bearing mice.
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Figure 1. Fluoxetine had no effect on tumor growth
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the
drinking water starting one day after tumor cell injection. A) Body weight was
monitored through the study. At the completion of the study, B) carcass weight, C)
gastrocnemius muscle mass, D) tumor mass, and E) spleen weight (n=12) were
analyzed using ANOVA. Means with * are different from control mice (p<0.05).

3.2 Effects of fluoxetine on tumor-induced fatigue
In this experiment, fatigue was modeled as a reduction in
VWRA.29 VWRA progressively declined starting at day 14 in tumorbearing mice (F1,38=48.33, p<0.0001) and there was no effect of
fluoxetine on VWRA (Fig.2).
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Figure 2. Fluoxetine had no effect on tumor-associated fatigue
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the
drinking water starting one day after tumor cell injection. Voluntary wheel running
activity (VWRA) was determined before tumor cell inoculation and again overnight on
days 8, 14 and 19 (n=12). Data are expressed as mean ± SEM and analyzed using
ANOVA. Means with * are different from control mice (p<0.05).

3.3 Effects of fluoxetine on tumor-induced depressivelike behavior
Depressive-like behavior was determined at 13 days after tumor
cell inoculation using the forced swim test (FST). Fig. 3A shows that
home cage locomotor activity was not different between any of the
groups, indicating that tumor bearing mice did not exhibit lethargy.
Fig. 3B&C show that tumor bearing mice became immobile sooner
than healthy control mice (F1,51=11.66, p<0.0013), and had increased
total time immobile in the FST (p<0.01). Tumor bearing mice treated
with fluoxetine, however, had decreased time to become immobile
(F1,51=9.90, p<0.0029) and also decreased total time immobile
(F1,52=6.48, p<0.014) compared to tumor mice that were not treated
with fluoxetine. There were no significant differences between tumor
bearing mice treated with fluoxetine and control mice. This dose of
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fluoxetine had no effect on locomotor activity or immobility during the
FST in healthy control mice, as was reported by others.31

Figure 3. Fluoxetine inhibited depressive-like behavior in tumor bearing mice
Control and tumor-bearing mice were administered fluoxetine in the drinking water
starting one day after tumor cell injection. A) Home cage activity was determined 13
days after tumor inoculation. Control and tumor mice were exposed to the forced swim
test (FST) at 13 days and B) latency to become immobile and C) total time immobile
(n=12) were analyzed using ANOVA. Bars represent the mean ± SEM. Means with *
are different from control (p<0.05).

3.4 Expression of brain cytokine mRNA
In a previous report, we demonstrated that tumor growth
increased IL-1β and IL-6 mRNA expression in the hippocampus at 2
weeks of tumor growth and that expression levels were further
increased by 3 weeks.17 In the present study, cytokine expression was
determined in the hippocampus at day 21 (week 3). By 21 days of
tumor growth, expression of IL-1β and IL-6 was increased in tumor
bearing mice compared to healthy controls (Fig.4A&B) (F1,27=10.71,
p<0.003). Fluoxetine administration had no effect on IL-1β or IL-6
mRNA expression in the hippocampus. Fluoxetine, however, tended to
reduce the expression of TNFα in both tumor-bearing and healthy
control mice (Fig.4C) (F1,28=3.66, p=0.06). There was a tendency for
KMO expression to be increased at 21 days of tumor growth
(F1,26=2.59, p=0.1), and there was no effect of fluoxetine on KMO
mRNA (Fig.4D). IDO expression was not altered with tumor growth or
fluoxetine administration (data not shown).
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Figure 4. Fluoxetine had no effect on tumor-induced pro-inflammatory cytokine
expression in the hippocampus
Control and tumor-bearing mice were administered fluoxetine (3mg/kg/day) in the
drinking water. A–D) IL-1β, IL-6, TNFα, and KMO mRNA expression was determined in
the hippocampus at 21 days (n=6–8). Data are expressed as mean ± SEM and were
analyzed using ANOVA. Means with * are different from control mice (p<0.05), means
with + tend to be different from control mice (p=0.1).

In conclusion, fluoxetine had no effect on tumor size, muscle
mass, inflammatory cytokine expression in the brain, or fatigue
behavior, but ameliorated depressive-like behavior in the tumorbearing mice.
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4. Discussion
Fatigue is a common and distressing symptom reported by
cancer patients before, during, and after cancer treatments.
Depressive symptoms are prevalent in patients with CRF and are
associated with higher mortality rates in patients with persistent or
incurable disease.32, 33 Therefore, treatments to reduce fatigue and
depression in cancer patients are needed to increase quality of life and
perhaps prolong survival. In this study, a mouse model of CRF was
used to determine the effects of fluoxetine, a SSRI, on behavioral
measures of depression and fatigue in tumor bearing mice. Here we
report that tumor-bearing mice demonstrate fatigue (decreased
VWRA) and depressed mood (increased immobility in FST) before
weight loss is evident. We have previously shown that fatigue and
depressive-like behavior in tumor-bearing mice is associated with
increased expression of IL-1β and IL-6 in the cortex and hippocampus,
brain regions associated with mood and motor activity.17 Treatment of
the tumor-bearing mice with fluoxetine did not affect tumor growth,
body weight, muscle mass, or cytokine expression in the brain.
However, fluoxetine reduced tumor-induced depressive-like behavior
in tumor-bearing mice. These findings explain in part previous reports
that treatment with an SSRI reduced depression, but did not reduce
fatigue in cancer patients undergoing chemotherapy.9, 10
Reduced VWRA is used to model fatigue in rodents in response
to immune challenge34 or chemotherapy.29 Consistent with our
previous study,17 we show that VWRA progressively decreases in
tumor bearing mice after day 14 of tumor growth with no change in
home cage locomotor activity. These findings indicate that tumor
growth did not cause general malaise or lethargy. Consistent with
clinical findings,9, 10 treatment with fluoxetine, a SSRI, did not affect
fatigue behavior in tumor-bearing mice.
Depression often co-occurs with fatigue and is frequently
reported by patients undergoing chemotherapy.7 In our mouse model
of CRF, tumor-bearing mice demonstrated depressive-like behavior in
the FST. We have previously shown that the increase in immobility in
the FST is not due to changes in muscle function, lethargy, or
malaise.17 Here we show that treatment with 3/mg/kg/day fluoxetine
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was sufficient to ameliorate depressive-like behavior in tumor-bearing
mice without changing mood-related behavior in healthy control
mice.31 Fluoxetine treatment had no effect on muscle mass, VWRA, or
home cage locomotor activity in tumor-bearing mice. These data
suggest the effects of fluoxetine were specific to tumor-induced
depressive-like behavior in these mice.
The underlying mechanisms of CRF are unknown but may be
related to a heightened inflammatory state.2 In rodent models of
inflammation and immune activation, elevated IL-1β expression in the
brain has been associated with fatigue and depression.16, 30 The results
of the present study support the hypothesis that tumor growth induces
neuroinflammation, which negatively affects mood which may play a
major role in the association of fatigue and depression in cancer
patients.4–6, 35, 36
Previous studies have shown anti-inflammatory effects of
fluoxetine on neuroinflammation. For example, fluoxetine decreased
TNFα and IL-1β expression in a rat model of stroke.37 In our study, we
show that peripheral inflammation (spleen weight) was not affected by
fluoxetine treatment, nor was brain expression of IL-1β and IL-6
mRNA. As shown in our previous study17 growth of this tumor did not
increase brain expression of TNFα mRNA; however, fluoxetine reduced
TNFα expression in the brain of both tumor-bearing and control mice.
Previous studies has shown that 5 mg/kg fluoxetine treatment
decreased plasma TNFα in mice injected with lipopolysaccharide38 and
reduced TNFα expression in immune activated microglia and monocyte
cell lines.39 It is possible that TNFα is a specific regulatory target of
fluoxetine treatment. It is also possible that administration of a higher
dose of fluoxetine may alter pro-inflammatory cytokine expression in
the brain. However, high doses of fluoxetine alter locomotor activity
which might confound our measures of home cage activity and VWRA
in the treated animals.27 Therefore we chose to use a relatively low
dose of fluoxetine in the present study. Overall, the reduced
depressive-like behavior in tumor bearing mice treated with fluoxetine
was not due to reduced expression of IL-1β, IL-6, IDO or KMO mRNA
in the brain of treated mice. We hypothesize that fluoxetine enhanced
serotonin activity in the brain without changing tumor-induced
neuroinflammation.
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Peripheral and CNS inflammation are also thought to induce
depressive-like behavior via increased activity of IDO and KMO, which
may reduce serotonin synthesis in the brain. Because proinflammatory cytokines can increase expression and activity of the IDO
enzyme40 and serotonin transporter,20 we suggest a link between
increased pro-inflammatory cytokines and decreased serotonin
availability in the tumor bearing mice. We and others have shown that
inhibiting IDO activity decreases serotonin turnover in the brain.40–42
As an SSRI, fluoxetine treatment reduces serotonin reuptake into the
presynaptic cell, which increases extracellular levels of serotonin in the
synaptic cleft that is available to bind to the postsynaptic receptor.
Tryptophan is the limiting factor for the synthesis of serotonin,
therefore, increased activity of IDO may alter serotonin availability and
turnover. In this study we show novel data that KMO expression was
greater in tumor-bearing mice than in control mice, which suggests
that tryptophan is shunted into the IDO and KMO-mediated pathway of
tryptophan metabolism. Previous studies showed that peripheral tumor
progression decreased serotonin levels in the hypothalamus of tumor
bearing mice.21, 43 Therefore, it is likely that altered serotonin
availability contributes to depressed mood associated with tumor
growth. Prior reports that SSRIs reduce depression in cancer
patients,9, 10 and our finding that fluoxetine inhibited depression-like
behavior in tumor bearing mice support this hypothesis. Further
research using methods such as microdialysis to determine free
serotonin in the cerebrospinal fluid of treated versus untreated tumorbearing mice is needed to confirm this hypothesis. Other explanations
for the beneficial effects of fluoxetine include improved neuronal
plasticity and neurogenesis. Recent studies using rodent models have
shown that neurogenesis is decreased in the hippocampus of tumor
bearing mice.23 In a model of chemotherapy, fluoxetine treatment
increased hippocampal neurogenesis and rescued memory
impairments induced by the chemotherapy treatment.44 Further
research is needed to determine if fluoxetine affected hippocampal
neurogenesis in our study, which may have played a role in reducing
depressive-like behaviors.
In conclusion, we show that a low dose (3mg/kg/day) of
fluoxetine administration is sufficient to reduce depressive-like
behaviors in tumor-bearing mice without altering other physiological
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effects of tumor growth. Consistent with clinical studies, fluoxetine had
no effect on tumor-induced fatigue behaviors in this animal model of
CRF. These data suggest that fatigue and depression associated with
CRF may be treated as two distinct symptoms.
Highlights
Tumor growth increased brain expression of pro-inflammatory
cytokines.
Fluoxetine had no effect on cytokine expression in tumor bearing mice.
Fluoxetine reduced depressive-like behaviors but not fatigue in tumor
bearing mice.
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